Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables: 2009-2024

Historic Change in Receivables for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$106,000.

  • Lineage Cell Therapeutics' Change in Receivables fell 176.92% to -$130,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$278,000, marking a year-over-year decrease of 717.65%. This contributed to the annual value of -$106,000 for FY2024, which is 123.77% down from last year.
  • Lineage Cell Therapeutics' Change in Receivables amounted to -$106,000 in FY2024, which was down 123.77% from $446,000 recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Change in Receivables high stood at $857,000 for FY2021, and its period low was -$50.3 million during FY2022.
  • Moreover, its 3-year median value for Change in Receivables was -$106,000 (2024), whereas its average is -$16.7 million.
  • In the last 5 years, Lineage Cell Therapeutics' Change in Receivables skyrocketed by 398.61% in 2021 and then slumped by 5,970.95% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Change in Receivables stood at -$287,000 in 2020, then skyrocketed by 398.61% to $857,000 in 2021, then plummeted by 5,970.95% to -$50.3 million in 2022, then soared by 100.89% to $446,000 in 2023, then tumbled by 123.77% to -$106,000 in 2024.